[Clinical impact of neoadjuvant treatment to radical prostatectomy in locally advanced prostatic cancer].
Thirty-five patients underwent a protocol of neo-adjuvant hormonal suppression previous to radical surgery in locally advanced stages, seven patients in stage B (T2) and 25 in stage C (T3). Three cases were not considered suitable for surgery since no clinical evidence of sub-staging was demonstrated. Clinical reassessment after neo-adjuvant therapy was conducted by rectal examination, PSA and transrectal ultrasound. Pre-hormonal average of PSA was 38.20 ng/ml (range: 1-235). Post-hormonal average was 1.15 ng/ml (range < 0.5-6.2). Clinical reduction of prostate volume was seen in 75% of patients. In three of them (9.37%) no tumour (Po) was seen in the pieces of prostatectomy.
Villavicencio
H
H
Fundación Puigvert, Barcelona.
Laguna
P
P
Ponce de Léon
J
J
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000726:Androgen Antagonists
Impacto clínico del tratamiento neoadyuvante a prostatectomía radical en el cáncer prostático localmente avanzado.